Share
13,321 Posts.
lightbulb Created with Sketch. 1237
clock Created with Sketch. 27/02/17
12:47
Share
Originally posted by windsurfar
↑
Oct 10 we had the Yervoy preliminary data release. The efficacy results exceeded my expectations, but the safety data was unexpected, in a very good way: no dose limiting toxicities in 17 patients treated with Yervoy/Cavatak combo. Only one grade 3 level fatigue as the only grade 3 or 4 toxicity!!! That just doesn't happen with the checkpoint inhibitors usually. It may be telling us of a truly outstanding benefit in that the viral infection could be redirecting the immune related activities against normal tissues that you normally see. One study i read had a 31% rate of grade 3 or 4 toxicities with Yervoy treatment.
Expand
Hi
